Compare Illumina, Inc. (ILMN) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs SkyWest Inc — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while SkyWest Inc trades at $96.52 (market cap $3.75B). The key difference: Illumina, Inc. is far larger — about 10.7× SkyWest Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and SkyWest Inc for 8 Days on average.
| ILMN | SKYW | |
|---|---|---|
Market Cap | $39.95B | $3.75B |
Volume | 3,169,503 | 196,324 |
Sector | Health | Industrials |
52-Week High | $293.69 | $115.94 |
52-Week Low | $91.00 | $78.40 |
Typical Hold Time | 83 Days | 8 Days |
Enterprise Value | $41.31B | $5.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
SkyWest (SKYW) trades at $96.73, up 0.09% on the day, with a bearish technical signal but strong fundamentals including a P/E of 9.6 and net income margin of 9.78%. Recent earnings show mixed results, with a Q1 2026 beat but a Q2 2026 miss. The company is expanding its fleet and flying agreements, supporting growth amid cost pressures.
The outlook is cautiously optimistic, with a consensus price target of $112 offering 16% upside. Risks include execution on cost control and competitive pressures, but low valuation and analyst buy ratings suggest potential for recovery if operational trends improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
